Surgery Partners, Inc. (NASDAQ:SGRY) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. decreased its position in Surgery Partners, Inc. (NASDAQ:SGRY) by 7.0% in the 4th quarter, HoldingsChannel reports. The firm owned 38,182 shares of the company’s stock after selling 2,882 shares during the period. Corebridge Financial Inc.’s holdings in Surgery Partners were worth $808,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Surgery Partners by 2.3% during the fourth quarter. Vanguard Group Inc. now owns 7,618,404 shares of the company’s stock worth $161,282,000 after purchasing an additional 172,271 shares during the last quarter. Geode Capital Management LLC boosted its stake in Surgery Partners by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,864,346 shares of the company’s stock worth $60,117,000 after buying an additional 42,897 shares during the last quarter. King Street Capital Management L.P. purchased a new stake in Surgery Partners in the 3rd quarter valued at about $46,748,000. American Century Companies Inc. increased its stake in shares of Surgery Partners by 223.9% during the 4th quarter. American Century Companies Inc. now owns 1,399,756 shares of the company’s stock valued at $29,633,000 after acquiring an additional 967,534 shares during the last quarter. Finally, E. Ohman J or Asset Management AB lifted its holdings in shares of Surgery Partners by 40.3% during the 4th quarter. E. Ohman J or Asset Management AB now owns 1,243,111 shares of the company’s stock worth $26,317,000 after acquiring an additional 357,023 shares during the period.

Insider Transactions at Surgery Partners

In other Surgery Partners news, insider Marissa Brittenham sold 3,156 shares of Surgery Partners stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $24.09, for a total transaction of $76,028.04. Following the sale, the insider now directly owns 63,408 shares in the company, valued at $1,527,498.72. The trade was a 4.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jason Eric Evans sold 26,520 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $25.65, for a total value of $680,238.00. Following the transaction, the chief executive officer now owns 560,698 shares of the company’s stock, valued at approximately $14,381,903.70. This trade represents a 4.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 106,622 shares of company stock valued at $2,717,860. Corporate insiders own 2.30% of the company’s stock.

Surgery Partners Stock Down 7.5 %

Shares of NASDAQ SGRY opened at $21.11 on Friday. The stock has a fifty day moving average price of $24.57 and a 200 day moving average price of $25.28. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99. Surgery Partners, Inc. has a 12-month low of $19.50 and a 12-month high of $33.97. The company has a market cap of $2.69 billion, a P/E ratio of -43.98, a P/E/G ratio of 19.21 and a beta of 2.40.

Surgery Partners (NASDAQ:SGRY) last announced its earnings results on Monday, March 3rd. The company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.38 by $0.01. The business had revenue of $864.40 million for the quarter, compared to the consensus estimate of $828.09 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. Research analysts anticipate that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.

Analyst Ratings Changes

SGRY has been the subject of several research analyst reports. Bank of America began coverage on shares of Surgery Partners in a research report on Monday, December 16th. They set a “buy” rating and a $30.00 price target for the company. Macquarie cut their target price on Surgery Partners from $34.00 to $33.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $35.00 price target on shares of Surgery Partners in a research report on Tuesday, March 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $36.63.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.